HC Wainwright Issues Pessimistic Forecast for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its target price lowered by research analysts at HC Wainwright from $240.00 to $180.00 in a report released on Thursday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 8.51% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Canaccord Genuity Group initiated coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Finally, Wolfe Research started coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $184.73.

Repligen Stock Down 1.2 %

Repligen stock opened at $165.89 on Thursday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market capitalization of $9.29 billion, a price-to-earnings ratio of -448.34, a PEG ratio of 4.51 and a beta of 0.97. The company’s 50 day simple moving average is $150.83 and its 200 day simple moving average is $146.05.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. During the same period last year, the firm posted $0.23 earnings per share. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Repligen will post 1.54 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RGEN. Dimensional Fund Advisors LP lifted its position in shares of Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after buying an additional 121,305 shares during the last quarter. Renaissance Technologies LLC bought a new position in Repligen in the 2nd quarter valued at approximately $5,320,000. Vanguard Personalized Indexing Management LLC boosted its position in Repligen by 3.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 5,125 shares of the biotechnology company’s stock valued at $646,000 after buying an additional 184 shares in the last quarter. Hsbc Holdings PLC grew its stake in shares of Repligen by 14.5% during the second quarter. Hsbc Holdings PLC now owns 14,178 shares of the biotechnology company’s stock worth $1,785,000 after buying an additional 1,791 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Repligen during the second quarter worth $164,000. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.